Sandoz’s Tyruko approved by FDA as first biosimilar for relapsing multiple sclerosis . The disease-modifying therapy is approved to treat all indications covered by Tysabri . Sandoz, a Novartis division, has announced that its biosimilar Tyruko (natalizumab-sztn) has been approved by the US Food and Drug Administration (FDA) to treat adults with relapsing forms of multiple sclerosis (MS). The disease-modifying therapy, developed by Polpharma Biologics, is a version of Tysabri (...